- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05502341
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)
Provozně bezproblémová randomizovaná, otevřená, multicentrická, aktivně kontrolovaná studie fáze 2/3 k vyhodnocení bezpečnosti a účinnosti biktegraviru/lenacapaviru versus stabilního základního režimu u virologicky potlačených lidí s HIV-1 na stabilních komplexních léčebných režimech
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Buenos Aires, Argentina, 1202
- Fundación Huésped
-
Buenos Aires, Argentina, 1072
- Hospital General de Agudos J.M Ramon Mejia
-
Buenos Aires, Argentina, 1425
- Helios Salud
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, Austrálie, 2010
- St.Vincent's Hospital Sydney
-
Darlinghurst, New South Wales, Austrálie, 2011
- Taylor Square Private Clinic
-
Sydney, New South Wales, Austrálie, 2010
- Holdsworth House Medical Practice
-
-
Victoria
-
Melbourne, Victoria, Austrálie, 3004
- Alfred Health
-
-
-
-
-
Santo Domingo, Dominikánská republika
- Instituto Dominicano de Estudio Virologicos - IDEV
-
-
-
-
-
Nice, Francie, 6202
- CHU Nice-Hôpital l'Archet
-
Paris, Francie, 75010
- Hospital Saint Louis
-
Paris, Francie, 75018
- Groupe Hospitalier Bichat Claude Bernard
-
Paris, Francie, 75651
- Höpital de la Pitié Salpêtrière
-
-
-
-
-
Milan, Itálie, 20157
- ASST Fatebenefratelli Sacco
-
Milan, Itálie, 20127
- IRCCS Ospedale San Raffaele
-
Modena, Itálie, 40124
- Azienda Ospedaliero-Universitaria di Modena
-
Roma, Itálie, 00149
- Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
-
Torino, Itálie, 10149
- ASL Città di Torino
-
-
-
-
-
Nagoya, Japonsko
- National Hospital Organization Nagoya Medical Center
-
Osaka, Japonsko, 540-0006
- National Hospital Organization Osaka National Hospital
-
Tokyo, Japonsko, 162-0052
- Center Hospital of the National Center for Global Health and Medicine
-
-
-
-
-
Cape Town, Jižní Afrika, 7925
- Desmond Tutu Health Foundation Clinical Trials Unit
-
Ga-Rankuwa, Jižní Afrika, 208
- Sefako Makgatho Health Sciences University
-
Johannesburg, Jižní Afrika, 2193
- Ezintsha
-
-
-
-
-
Daegu, Jižní Korea, 41944
- Kyungpook National University Hospital
-
Daejeon, Jižní Korea, 35015
- Chungnam National University Hospital
-
Seoul, Jižní Korea, 06591
- The Catholic University of Korea Seoul St. Mary's Hospital
-
Seoul, Jižní Korea, 03722
- Yonsei University Severance Hospital
-
-
-
-
-
Decarie Montreal, Kanada, H4A 3J1
- Chronic Viral Illness Service / McGill University Health Centre (MUHC)
-
Montreal, Kanada, H2L 0B1
- Clinique Medicale du Quartier Latin
-
Ottawa, Kanada, K1H 8L6
- The Ottawa Hospital - General Campus
-
Regina, Kanada, S4P 0W5
- ID Clinic
-
Toronto, Kanada, M5G 1K2
- Maple Leaf Research
-
Vancouver, Kanada, V6Z 2T1
- Spectrum Health
-
-
-
-
-
Berlin, Německo, 10439
- zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
-
Bonn, Německo, 53127
- Universitatsklinikum Bonn
-
Frankfurt, Německo, 60596
- Infektio Research GmbH & Co.KG
-
Hamburg, Německo, 20146
- ICH Study Center GmbH & Co. KG
-
München, Německo
- MVZ München am Goetheplatz
-
-
-
-
PR
-
San Juan, PR, Portoriko, 00909
- Hope Clinical Research
-
San Juan, PR, Portoriko, 00935
- Proyecto ACTU
-
-
-
-
-
Birmingham, Spojené království, B9 5SS
- Department of HIV & Sexual Medicine
-
Brighton, Spojené království, BN2 3EW
- Brighton and Sussex University Hospitals NHS Trust
-
London, Spojené království, E1 1BB.
- Barts Health NHS Trust
-
London, Spojené království, SE5 9RS
- HIV medicine and infectious diseases
-
London, Spojené království, SW109NH
- St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre
-
-
-
-
California
-
Berkeley, California, Spojené státy, 48072
- Be Well Medical Center
-
Beverly Hills, California, Spojené státy, 90211
- Pacific Oaks Medical Group
-
Los Angeles, California, Spojené státy, 90036
- Ruane Clinical Research Group, Inc
-
Oakland, California, Spojené státy, 94609
- Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
-
Palm Springs, California, Spojené státy, 92262
- Bios Clinical Research
-
San Diego, California, Spojené státy, 92103
- University of California San Diego (UCSD)
-
Torrance, California, Spojené státy, 90502
- Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
-
West Hollywood, California, Spojené státy, 90046
- The Men's Health Foundation
-
-
Colorado
-
Denver, Colorado, Spojené státy, 80204
- Denver Health Medical Center
-
-
Connecticut
-
New Haven, Connecticut, Spojené státy, 06510
- Yale University; School of Medicine; AIDS Program
-
-
Florida
-
DeLand, Florida, Spojené státy, 32720
- Midland Florida Clinical Research Center, LLC
-
Fort Lauderdale, Florida, Spojené státy, 33316
- Gary Richmond, MD, PA, Inc.
-
Fort Lauderdale, Florida, Spojené státy, 33308
- Therafirst Medical Centers
-
Ft. Pierce, Florida, Spojené státy, 34982
- Midway Immunology & Research Center, LLC
-
Miami, Florida, Spojené státy, 33136
- Schiff Center for liver Diseases/University of Miami
-
Miami Lakes, Florida, Spojené státy, 33016
- Floridian Clinical Research
-
Orlando, Florida, Spojené státy, 32803
- Orlando Immunology Center
-
Orlando, Florida, Spojené státy, 32803
- Therapeutic Concepts, PA
-
West Palm Beach, Florida, Spojené státy, 33407
- Triple O Research Institute PA
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30309
- Atlanta ID Group
-
Macon, Georgia, Spojené státy, 31201
- Mercer University School of Medicine
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60613
- Howard Brown Health Center
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64111
- Kansas City Care Clinic
-
St Louis, Missouri, Spojené státy, 63139
- Southampton Healthcare, Inc.
-
-
New Jersey
-
Newark, New Jersey, Spojené státy, 07102
- Saint Michael's Medical Center
-
-
New Mexico
-
Santa Fe, New Mexico, Spojené státy, 87505
- AXCES Research Group
-
-
New York
-
Flushing, New York, Spojené státy, 11355
- New York Presbyterian Hospital
-
New York, New York, Spojené státy, 10001
- Ricky K. Hsu, MD, PC
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27514
- University of North Carolina - Chapel Hill
-
Greenville, North Carolina, Spojené státy, 27858
- East Carolina University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Philadelphia FIGHT
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina (MUSC) Research NEXUS
-
-
Texas
-
Austin, Texas, Spojené státy, 78705
- Central Texas Clinical Research
-
Bellaire, Texas, Spojené státy, 77401
- St. Hope Foundation
-
Dallas, Texas, Spojené státy, 75246
- North Texas Infectious Diseases Consultants
-
Dallas, Texas, Spojené státy, 75208
- AIDS Arms, Inc., DBA Prism Health North Texas
-
Fort Worth, Texas, Spojené státy, 76104
- Texas Centers for Infectious Disease Associates
-
Houston, Texas, Spojené státy, 77098
- Gordon E. Crofoot MD PA
-
Longview, Texas, Spojené státy, 75605
- Diagnostic Clinic of Longview - Center for Clinical Research
-
-
Washington
-
Seattle, Washington, Spojené státy, 98104
- Peter Shalit, MD
-
-
-
-
-
Kaohsiung City, Tchaj-wan, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Kaohsiung City, Tchaj-wan, 81362
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
New Taipei City, Tchaj-wan, 22060
- Far Eastern Memorial Hospital
-
Taoyuan City, Tchaj-wan, 33004
- Taoyuan General Hospital
-
-
-
-
-
Barcelona, Španělsko, 08036
- Hospital Clinic Provincial de Barcelona
-
Madrid, Španělsko, 28040
- Hospital Clinico San Carlos
-
Madrid, Španělsko, 28046
- Hospital Universitario La Paz
-
Madrid, Španělsko, 28034
- Hospital Ramon y Cajal, Madrid
-
Seville, Španělsko, 4103
- Hospital Universitario Virgen del Rocio
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Key Inclusion Criteria:
-
If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.
-
At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL
-
Plasma HIV-1 RNA levels < 50 copies/mL at screening.
-
Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:
- A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
- A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
- A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
-
No documented or suspected resistance to bictegravir (BIC).
-
Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.
Key Exclusion Criteria:
- Prior use of, or exposure to, lenacapavir (LEN)
- Active tuberculosis infection
- Chronic hepatitis B virus (HBV) infection
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg
Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1. Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP) |
Tablets administered orally without regard to food
Ostatní jména:
Tablets administered orally without regard to food
Ostatní jména:
|
|
Experimentální: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg
Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP. |
Tablets administered orally without regard to food
Ostatní jména:
Tablets administered orally without regard to food
Ostatní jména:
|
|
Aktivní komparátor: Phase 2: Treatment Group 3: SBR
Participants will continue with their SBR for up to 24 weeks. Participants who discontinue early or complete the RP will have an option to continue in EP. |
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
|
Experimentální: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC
Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1. Participants who discontinue early or complete the RP will have an option to continue in EP. |
Tablets administered orally without regard to food
Ostatní jména:
|
|
Aktivní komparátor: Phase 3: Treatment Group 2: SBR
Participants will continue with their SBR for up to 48 weeks. Participants who will discontinue early or complete the RP had an option to continue in EP. |
SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).
|
|
Experimentální: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC
At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP). |
Tablets administered orally without regard to food
Ostatní jména:
Tablets administered orally without regard to food
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Časové okno: Week 24
|
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off. |
Week 24
|
|
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Časové okno: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off. |
Week 48
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
Časové okno: Week 24
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off. |
Week 24
|
|
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Časové okno: Baseline, Week 24
|
Baseline, Week 24
|
|
|
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
Časové okno: First dose date up to Week 24
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off. |
First dose date up to Week 24
|
|
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
Časové okno: At Week 16 or 24
|
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or 24
|
|
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
Časové okno: At Week 16 or Week 24
|
Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: AUCtau of BIC at Steady State
Časové okno: At Week 16 or 24
|
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or 24
|
|
Phase 2: PK Parameter: AUCtau for LEN at Steady State
Časové okno: At Week 16 or Week 24
|
AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: Ctrough of BIC at Steady State
Časové okno: At Week 16 or Week 24
|
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 2: PK Parameter: Ctrough of LEN at Steady State
Časové okno: At Week 16 or Week 24
|
Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit. |
At Week 16 or Week 24
|
|
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Časové okno: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). |
Week 48
|
|
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
Časové okno: Baseline, Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off. |
Baseline, Week 48
|
|
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
Časové okno: First dose date up to Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off. |
First dose date up to Week 48
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Časové okno: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Časové okno: Week 144
|
Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Časové okno: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Časové okno: Week 144
|
Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Časové okno: Baseline, Week 96
|
Baseline, Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Časové okno: Baseline, Week 144
|
Baseline, Week 144
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Časové okno: Week 96
|
Week 96
|
|
|
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Časové okno: Week 144
|
Week 144
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Obecné publikace
- Arora P, Hindman JT, West S, Ling J, Palaparthy R, Marathe DD. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study. Antimicrob Agents Chemother. 2026 Jan 7;70(1):e0078125. doi: 10.1128/aac.00781-25. Epub 2025 Nov 28.
- Orkin C, Ruane PJ, Hedgcock M, Gaultier C, Losso MH, Trottier B, Lutz T, O'Reilly M, Bloch M, Slim J, Ramgopal M, Sokhela S, Mounzer K, Tsai HC, Santana Bagur J, Zhang X, Aizen K, Price K, Margot N, Montezuma-Rusca JM, Sklar P, Rhee M, Cahn P; ARTISTRY-1 Study Group. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. Lancet. 2026 Mar 28;407(10535):1249-1258. doi: 10.1016/S0140-6736(26)00307-7. Epub 2026 Feb 25.
- Ph2 PK data was included as part of the 2024 HIV-G presentation: https://hivglasgow.org/wp-content/uploads/2025/02/P049_Arora.pdf
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- GS-US-621-6289
- 2022-500929-33 (Jiný identifikátor: European Medicines Agency)
- DOH-27-052023-8574 (Jiný identifikátor: South African Clinical Trial Registry)
- jRCT2051230168 (Jiný identifikátor: Japan registry)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .